Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. is a pioneering biotechnology company that specializes in discovering and developing RNA-targeted therapeutics. Founded in 1989 by Dr. Stanley T. Crooke, Ionis has been at the forefront of innovation in the field of antisense technology, which is designed to alter the genetic instructions within cells to treat various diseases. The company is headquartered in Carlsbad, California. As of 2023, Ionis is led by CEO Brett P. Monia, who has continued to advance the company's mission to address significant unmet medical needs. Ionis has achieved notable success with several approved drugs, and its diverse pipeline is focused on treating rare diseases, neurological disorders, and cardiovascular conditions, among others. The company collaborates globally with partners to enhance the reach and impact of its discoveries. Ionis reported revenues of approximately $587 million in 2022, reflecting its active portfolio and collaborative projects with major pharmaceutical companies. Known for its commitment to science and its innovative approach, Ionis Pharmaceuticals remains a key player in the biotechnology landscape.